S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:AQST

Aquestive Therapeutics - AQST Stock Forecast, Price & News

$0.89
-0.01 (-1.11%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.88
$0.91
50-Day Range
$0.84
$1.18
52-Week Range
$0.62
$6.25
Volume
152,175 shs
Average Volume
599,596 shs
Market Capitalization
$48.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.13

Aquestive Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
922.5% Upside
$9.10 Price Target
Short Interest
Healthy
4.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Aquestive Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.18) to ($0.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

488th out of 1,027 stocks

Pharmaceutical Preparations Industry

215th out of 503 stocks

AQST stock logo

About Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AQST Stock News Headlines

Aquestive Therapeutics: Going All-In On AQST-109
Aquestive Therapeutics Earnings Preview
Why Is Aquestive Therapeutics Stock Up Today?
Where Aquestive Therapeutics Stands With Analysts
Aquestive Therapeutics: A First Take
See More Headlines
Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AQST Company Calendar

Last Earnings
11/02/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/14/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AQST
Fax
N/A
Employees
157
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.10
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+700.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-70,540,000.00
Net Margins
-147.69%
Pretax Margin
-147.69%

Debt

Sales & Book Value

Annual Sales
$50.83 million
Book Value
($2.05) per share

Miscellaneous

Free Float
48,876,000
Market Cap
$48.20 million
Optionable
Not Optionable
Beta
2.80

Key Executives

  • Mr. Daniel Barber (Age 46)
    CEO, Pres & Director
    Comp: $750.28k
  • Mr. A. Ernest Toth Jr. (Age 63)
    Sr. VP & CFO
    Comp: $679.9k
  • Mr. Keith J. Kendall (Age 64)
    Consultant
    Comp: $1.03M
  • Mr. Alexander Mark Schobel (Age 63)
    Chief Innovation & Technology Officer
  • Ms. Lori J. Braender BSBA (Age 66)
    Esq., J.D., Sr. VP & Gen. Counsel
  • Dr. Eric Dadey Ph.D.
    Sr. Vice-Pres of R&D
  • Mr. Peter E. Boyd (Age 56)
    Sr. VP of Bus. Process & Information Technology
  • Mr. Kenneth W. Marshall (Age 63)
    Sr. VP & Chief Commercial Officer
  • Dr. Kenneth Truitt M.D.
    Chief Medical Officer
  • Mr. Robert Charles Arnold
    VP of Fin., Controller & Assistant Sec.













AQST Stock - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings
or view top-rated stocks.

What is Aquestive Therapeutics' stock price forecast for 2023?

5 brokerages have issued 1 year price objectives for Aquestive Therapeutics' shares. Their AQST share price forecasts range from $5.00 to $17.00. On average, they anticipate the company's stock price to reach $9.10 in the next year. This suggests a possible upside of 922.5% from the stock's current price.
View analysts price targets for AQST
or view top-rated stocks among Wall Street analysts.

How have AQST shares performed in 2022?

Aquestive Therapeutics' stock was trading at $3.89 on January 1st, 2022. Since then, AQST shares have decreased by 77.1% and is now trading at $0.89.
View the best growth stocks for 2022 here
.

Are investors shorting Aquestive Therapeutics?

Aquestive Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 2,430,000 shares, a decrease of 7.3% from the October 31st total of 2,620,000 shares. Based on an average daily volume of 650,000 shares, the short-interest ratio is currently 3.7 days.
View Aquestive Therapeutics' Short Interest
.

When is Aquestive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our AQST earnings forecast
.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The company earned $13.29 million during the quarter, compared to analyst estimates of $12.03 million. During the same quarter last year, the business posted ($0.49) EPS.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $46.00 million-$49.00 million, compared to the consensus revenue estimate of $47.01 million.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), OrganiGram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.18%), Renaissance Technologies LLC (1.66%) and Vahanian & Associates Financial Planning Inc. (1.30%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, John T Maxwell, Keith J Kendall, Lori J Braender and Peter E Boyd.
View institutional ownership trends
.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $0.89.

How much money does Aquestive Therapeutics make?

Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $48.20 million and generates $50.83 million in revenue each year. The company earns $-70,540,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Aquestive Therapeutics have?

The company employs 157 workers across the globe.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com.

This page (NASDAQ:AQST) was last updated on 12/8/2022 by MarketBeat.com Staff